Measured Solutions for Health (MESH) has been serving the pharmaceutical industry for almost 20 years, providing expert advice on the application and interpretation of Patient Reported Outcome Measures (PROMs), validity testing and cultural adaptation.
We are the sole licence provider of the RiiQTM (Respiratory Infection Intensity and Impact Questionnaire) and the flu-iiQTM (Influenza Intensity and Impact Questionnaire).
The RiiQ™ was developed and tested from 2016 to 2023 and is based on the flu-iiQ™, the most widely used and trusted influenza PROM globally. The RiiQ™ and flu-iiQ™ have been translated to over 50 languages and are widely used by leading pharmaceutical companies and research teams to determine the effectiveness of new respiratory infection vaccines and pharmaceuticals.
Developed and tested using a validity-driven approach, in which the needs of the pharmaceutical industry and the requirements of regulatory bodies such as the FDA were very carefully considered, the RiiQ™ and the flu-iiQ™ meet and exceed modern psychometric standards. The flu-iiQ™ is the only influenza tool included in the FDA CDISC initiative.
The RiiQ™ was developed in collaboration with Janssen Pharmaceuticals to generate a new evidence-based PROM for a broad range of respiratory infections, including Respiratory Syncytial Virus (RSV), influenza and other influenza-like illnesses (ILS).
Our expertise
Our principal scientist and the lead developer of the flu-iiQ™ and RiiQ™ is Dr Richard Osborne PhD, a global expert in Patient Reported Outcome Measure (PROM) development and validation. Dr Osborne has developed over 10 PROMs, several of which are used worldwide. He has published over 300 peer reviewed scientific papers, over 100 of which specifically focus on PROM development, validation and application. His work has been published widely, including in prestigious journals such as NEJM, The Lancet, British Medical Journal, Value in Health, Quality of Life Research, and many others.
Dr Osborne has chaired more than 200 translation and cultural adaption consensus meetings and has developed new theory and practice in this setting. As an epidemiologist, he has undertaken numerous clinical trials and brings extensive knowledge and experience in trial design, analytical approaches and publication know-how.
